SUPERIO BIO AS
Operating
Forskning og utvikling av legemidler samt alt som står i naturlig
sammenheng med dette.
Forskning og utvikling av legemidler.
Organization
- CEO
- JT
- Chairman of the board
- IS
Inger Sandlie1953
- Years since formation
- 1 year
- since Apr 26, 2025
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 0
Financials
- Total operating income 2025
- 371,500
- NOK
- Annual total result 2025
- -28,023
- NOK
- Total equity 2025
- 1,977
- NOK
Last update: Jun 27, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
JT | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
IS 1953 | Chairman | - |
JT | Board Member | - |
AK 1991 | Board Member | - |
PH | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Accountant | - |
Last update: Jun 10, 2026
Ownership
No available data
Financials
in NOK
Summary
| Year | 2025 |
|---|---|
Total operating income | 371,500 |
Annual Total Result | -28,023 |
Total assets | 472,099 |
Total liabilities | 470,122 |
Total equity | 1,977 |
P&L
| Year | 2025 |
|---|---|
Total operating income | 371,500 |
Total operating costs | 399,522 |
Operating result | -28,022 |
Financial income/costs | -1 |
Profit before tax | -28,023 |
Total tax & extraordinary income/cost | 0 |
Annual Total Result | -28,023 |
Balance overview
| Year | 2025 |
|---|---|
Total fixed assets | 194,500 |
Total current assets | 277,599 |
Total assets | 472,099 |
Short term debt | 470,122 |
Long term debt | 0 |
Total liabilities | 470,122 |
Contributed capital | 30,000 |
Retained earnings | -28,023 |
Total equity | 1,977 |
Total equity and liabilities | 472,099 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises